Valuation: H. Lundbeck A/S

Capitalization 36.71B 5.71B 4.91B 4.41B 4.26B 7.74B 525B 8.12B 52.29B 20.95B 251B 21.43B 20.97B 900B P/E ratio 2026 *
8.77x
P/E ratio 2027 * 8.63x
Enterprise value 40.92B 6.36B 5.47B 4.92B 4.74B 8.63B 585B 9.05B 58.29B 23.35B 280B 23.89B 23.38B 1,004B EV / Sales 2026 *
1.61x
EV / Sales 2027 * 1.43x
Free-Float
30.74%
Yield 2026 *
3.71%
Yield 2027 * 3.77%
1 day-1.51%
1 week-1.56%
Current month-2.48%
1 month+2.16%
3 months-15.63%
6 months-8.83%
Current year-12.47%
1 week 37.52
Extreme 37.52
40.1
1 month 37.52
Extreme 37.52
41.48
Current year 35.3
Extreme 35.3
47.04
1 year 27.2
Extreme 27.2
47.78
3 years 27.2
Extreme 27.2
49.38
5 years 23.3
Extreme 23.295
49.38
10 years 23.3
Extreme 23.295
49.38
Manager TitleAgeSince
Chief Executive Officer 59 30/09/2023
Director of Finance/CFO 49 31/08/2022
Chief Operating Officer 52 -
Director TitleAgeSince
Director/Board Member 66 24/03/2015
Director/Board Member 66 24/03/2015
Director/Board Member 60 19/03/2018
Change 5d. change 1-year change 3-years change Capi.($)
-1.51%-1.56%-4.55%+27.21% 5.76B
-1.30%-5.66%+43.72%+165.94% 114B
+0.81%-4.12%+70.92%+189.60% 50.83B
+1.79%-3.06%-1.38% - 22.5B
+3.46%-2.10%+1.77%-23.94% 8.59B
-0.29%-3.19%+4.98%-5.23% 8.27B
+0.65%-0.46%-10.03%-12.86% 8.22B
+0.21%-1.42%+13.82%+27.14% 5.93B
-0.24%-2.30%+29.67%+62.00% 3.82B
+1.74%0.00%+4.78%-3.18% 3.74B
Average +0.53%-1.50%+15.37%+47.41% 23.17B
Weighted average by Cap. -0.16%-0.90%+37.64%+137.43%

Financials

2026 *2027 *
Net sales 25.37B 3.95B 3.39B 3.05B 2.94B 5.35B 363B 5.61B 36.15B 14.48B 174B 14.81B 14.49B 622B 25.52B 3.97B 3.41B 3.07B 2.96B 5.38B 365B 5.64B 36.35B 14.56B 175B 14.89B 14.58B 626B
Net income 4.27B 665M 572M 514M 496M 901M 61.1B 945M 6.09B 2.44B 29.28B 2.49B 2.44B 105B 4.57B 711M 611M 549M 530M 964M 65.31B 1.01B 6.51B 2.61B 31.3B 2.67B 2.61B 112B
Net Debt 4.22B 656M 564M 507M 489M 889M 60.26B 932M 6B 2.41B 28.88B 2.46B 2.41B 103B -209M -32.55M -27.99M -25.15M -24.27M -44.14M -2.99B -46.28M -298M -119M -1.43B -122M -120M -5.13B
Logo H. Lundbeck A/S
H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and schizophrenia. Its product portfolio includes: Cipralex for the treatment of depression and anxiety disorders, Ebixa for the treatment of Alzheimer’s disease, Azilect for the treatment of Parkinson’s disease, Xenazine for the treatment of Huntington’s disease and Sabril for the treatment of epilepsy, among others. The Company operates through a number of subsidiaries, such as Lundbeck SAS, Lundbeck GmbH, SIA Lundbeck Latvia and Lundbeck LLC.
Employees
5,039
Date Price Change Volume
06/03/26 37.78 kr -1.51% 654,045
05/03/26 38.36 kr -0.42% 723,019
04/03/26 38.52 kr +1.32% 700,876
03/03/26 38.02 kr -2.66% 763,838
02/03/26 39.06 kr +0.83% 808,842
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
37.78DKK
Average target price
46.12DKK
Spread / Average Target
+22.09%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. HLUN B Stock